孕激素受体与颅底脑膜瘤良性生物学行为相关
该回顾性研究纳入161例脑膜瘤手术患者(颅底61例、非颅底100例),分析雌激素受体、孕激素受体(PGR)及Ki-67免疫组化数据。颅底脑膜瘤全切率显著低于非颅底(50.8% vs 77.0%,P=0.0006),但复发率及无复发生存无差异;颅底脑膜瘤PGR阳性比例显著更高(61.5±33.4% vs 42.2±35.7%,P=0.0009),作者认为高PGR阳性率可能解释其良性生物学行为。
要点
- 颅底脑膜瘤全切率50.8%显著低于非颅底77.0%(P=0.0006)。
- 两部位间复发率及无复发生存无差异,Ki-67指数与WHO分级亦无差异。
- 颅底脑膜瘤PGR阳性比例显著更高(61.5±33.4% vs 42.2±35.7%,P=0.0009)。
核心结论
- 颅底脑膜瘤常难以完全切除,但颅底与非颅底脑膜瘤的无复发生存及复发率无差异。
- 因两部位间Ki-67指数与WHO分级无差异,高PGR阳性率可能解释颅底脑膜瘤的良性生物学行为。
研究设计与样本
- 回顾性分析在本研究所接受手术切除的脑膜瘤患者,纳入具有雌激素受体、PGR和Ki-67免疫组化染色数据的患者。
- 共纳入161例患者,其中颅底脑膜瘤61例、非颅底脑膜瘤100例。
主要发现
- 组织学WHO I、II、III级患者分别为132例(82.0%)、22例(14.7%)、7例(4.4%)。
- 肿瘤复发见于21例(13.0%)。
- PGR阴性、高Ki-67指数、不完全切除及WHO II或III级与肿瘤复发及较短无复发生存显著相关。
- 颅底脑膜瘤31例(50.8%)与非颅底脑膜瘤77例(77.0%)实现总体完全切除(P=0.0006)。
- 颅底脑膜瘤PGR阳性比例显著高于非颅底(61.5±33.4% vs 42.2±35.7%,P=0.0009)。
关键数值与推荐
- Ki-67指数、WHO II或III级比例、复发率及无复发生存率在肿瘤部位间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Many studies have been performed to evaluate the roles of estrogen receptor and progesterone receptor (PGR) in meningiomas, but their influence on tumor behavior remains unclear. METHODS: We retrospectively analyzed patients with meningioma who underwent surgical resection at our institute. Patients with data for immunohistochemical staining of estrogen receptor, PGR, and Ki-67 were included. RESULTS: The study included 161 patients comprising 61 skull base and 100 non-skull base meningiomas. Histologically, the number of patients with World Health Organization (WHO) grade I, II, and III disease were 132 (82.0%), 22 (14.7%), and 7 (4.4%), respectively. Tumor recurrence was observed in 21 (13.0%). Negative PGR, high Ki-67 index, incomplete resection, and WHO grade II or III were significantly correlated with tumor recurrence and shorter recurrence-free survival. Skull base meningiomas were difficult to remove entirely; 31 patients (50.8%) with skull base and 77 patients (77.0%) with non-skull base meningiomas had overall complete removal (P = 0.0006). Ki-67 indices, proportion of WHO grade II or III, and recurrence rate or recurrence-free survival did not differ between the tumor locations. The only difference was the proportion of patients with positive PGR, which was significantly higher for skull base meningiomas (61.5 ± 33.4% vs. 42.2 ± 35.7%, P = 0.0009). CONCLUSIONS: Although skull base meningiomas are often incompletely resected, there were no differences in recurrence-free survival or recurrence rate between skull base and non-skull base meningiomas. As the Ki-67 index and WHO grade were not different between these locations, the high rate of positive PGR may be responsible for the benign biology of skull base meningiomas.
引用
- Kuroi Y, Matsumoto K, Shibuya M, et al. Progesterone Receptor Is Responsible for Benign Biology of Skull Base Meningioma. World Neurosurg. 2018. PMID: 30031954. doi:10.1016/j.wneu.2018.07.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。